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Sarkis M Minasian1,2, Michael M Galagudza1,2, Yuri V Dmitriev1*, Dmitry I Kurapeev1 and Timur D Vlasov1,2Abstract
Background: The Krebs-Henseleit buffer is the best perfusion solution for isolated mammalian hearts. We
hypothesized that a Krebs-Henseleit buffer-based cardioplegic solution might provide better myocardial protection
than well-known crystalloid cardioplegic solutions because of its optimal electrolyte and glucose levels, presence of
buffer systems, and mild hyperosmolarity.
Methods: Isolated Langendorff-perfused rat hearts were subjected to either global ischemia without cardioplegia
(controls) or cardioplegic arrest for either 60 or 180 min, followed by 120 min of reperfusion. The modified Krebs-
Henseleit buffer-based cardioplegic solution (mKHB) and St. Thomas’ Hospital solution No. 2 (STH2) were studied.
During global ischemia, the temperatures of the heart and the cardioplegic solutions were maintained at either
37°C (60 min of ischemia) or 22°C (moderate hypothermia, 180 min of ischemia). Hemodynamic parameters were
registered throughout the experiments. The infarct size was determined through histochemical examination.
Results: Cardioplegia with the mKHB solution at moderate hypothermia resulted in a minimal infarct size (5 ± 3%)
compared to that in the controls and STH2 solution (35 ± 7% and 19 ± 9%, respectively; P < 0.001, for both groups
vs. the mKHB group). In contrast to the control and STH2-treated hearts, no ischemic contracture was registered in
the mKHB group during the 180-min global ischemia. At normothermia, the infarct sizes were 4 ± 3%, 72 ± 6%, and
70 ± 12% in the mKHB, controls, and STH2 groups, respectively (P < 0.0001). In addition, cardioplegia with mKHB at
normothermia prevented ischemic contracture and improved the postischemic functional recovery of the left
ventricle (P < 0.001, vs. STH2).
Conclusions: The data suggest that the Krebs-Henseleit buffer-based cardioplegic might be superior to the
standard crystalloid solution (STH2).
Keywords: Heart, Ischemia/reperfusion injury, Myocardial protection/cardioplegiaBackground
Myocardial protection against global ischemia-reperfusion
injury during open-heart surgery with cardiopulmo-
nary bypass and cardioplegic arrest remains a challen-
ging problem [1]. Despite recent advances, such factors
as progressive aging of patients, the occurrence of co-
morbidities, and preexisting severe myocardial dysfunc-
tion require further improvements in intraoperative
cardiac protection [2,3].* Correspondence: yury.v.dmitriev@gmail.com
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reproduction in any medium, provided the orCurrently, it is well established that isothermic blood
cardioplegia provides robust myocardial protection and re-
sults in lesser myocardial injury, as detected on bio-
chemical examination, and better outcomes than cold
crystalloid cardioplegia [4-6]. However, blood cardioplegia
has some limitations, including increased risk of systemic
hyperkalemia [7] and technical problems in pediatric, par-
ticularly neonatal, cardiac surgery [8,9]. Surgical treatment
of complex congenital heart defects in neonates is usually
associated with an extended duration of anoxia, therefore
requiring particularly careful myocardial protection. Con-
sequently, the development of novel and improved crystal-
loid cardioplegic solutions may be necessary. Given thatal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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option for perfusion of the isolated mammalian heart,
KHB-based cardioplegia may be an interesting option. In
the literature, only 1 report is available on the feasibi-
lity of myocardial protection by a modified KHB [10]. In
this study, a modified KHB with increased potassium (20
mmol/L) and calcium concentrations (0.1–2.5 mmol/L)
was used for continuous coronary perfusion of the isolated
rat heart for 180 min at 37°C. Minimal myocardial injury
was found when the hearts were perfused with a solution
containing 1.5 mmol/L calcium.
We hypothesized that a KHB-based crystalloid cardio-
plegic solution provides superior myocardial protection
compared to that provided by a well-accepted solution,
that is, St Thomas’ Hospital cardioplegic solution No. 2
(STH2). The purpose of the present study was to com-
pare the protective effect of KHB-based cardioplegia
with that of STH2-based cardioplegia during normother-




Adult male Wistar rats (body weight, 250–320 g) were
used throughout the experiments. All the animals re-
ceived humane care in accordance with the European
Convention on Animal Care regulations. The study was
approved by the ethics committee of V. A. Almazov
Federal Heart, Blood and Endocrinology Centre, Saint
Petersburg, Russian Federation.
Perfusion of isolated hearts
The rats were anesthetized with sodium pentobarbital
(60 mg/kg intraperitoneally). Heparin was not adminis-
tered before heart excision. Each heart was excised via
bilateral thoracotomy and perfused through the ascend-
ing aorta with KHB consisting of the following
(in mmol/L), at a constant pressure of 85 mm Hg: NaCl,
118.5; KCl, 4.7; NaHCO3, 25; KH2PO, 1.2; MgSO4, 1.2;
glucose, 11; and CaCl2, 1.5. Perfusion pressure was
maintained by gravity, that is, by using a water-jacketed
double-walled glass column connected to the aortic can-
nula via a 3-way stopcock. The oxygenation of KHB was
performed with carbogen (95% O2 plus 5% CO2) deliv-
ered through the inverted fritted glass filter to maintain
pO2 ≥ 500 mm Hg. The time interval between the open-
ing of the thoracic cavity and initiation of perfusate flow
to the heart was < 80 s.
Heart function was stabilized for 15 min before
cardioplegic arrest. Left ventricular systolic (LVSP) and
end-diastolic pressures (LVEDP) were measured isovo-
lumetrically using a nonelastic polyethylene balloon intro-
duced into the left ventricle via the left atrium. The
balloon was coupled to an insulin syringe and inflated with0.4–0.6 mL of boiled water to obtain a LVEDP < 10 mm
Hg during stabilization. Software (PhysExp Gold, Cardio-
protect Ltd., Saint Petersburg, Russian Federation) was
used to process the pressure wave recorded using a mini-
ature pressure transducer (Baxter International, Deerfield,
Ill., USA) and produce every minute a value corresponding
to the mean LVEDP and LVSP. Left ventricular developed
pressure (LVDP) was calculated as LVSP − LVEDP. Heart
rate (HR) was derived from the pressure wave. Coronary
flow rate (CFR) was measured by timed collection of the
perfusate outflow.
The temperatures of the heart and cardioplegic solu-
tions during global ischemia were maintained at either
37°C (normothermia) or 22°C (moderate hypothermia).
The heart temperature was maintained between cardio-
plegia infusions by means of heart immersion into a
buffer-filled water-jacketed glass chamber. The tempe-
rature in the chamber was maintained using a thermo-
circulator. The myocardial temperature was monitored
using a miniature temperature probe inserted into the
right ventricular cavity through a small incision in the
pulmonary artery.
In the normothermia series, the cardioplegic solution
was administered antegradely at a constant pressure of
85 mm Hg at the start and after 20 and 40 min of global
ischemia for 4, 2, and 2 min, respectively. The amount
of cardioplegic solution given during each administra-
tion was approximately 30–40% more than the baseline
CFR, possibly owing to the rapid cessation of cardiac
contractions.
In the hypothermia series, 9 infusions of the cardio-
plegic solutions were performed during each 20 minutes
of global ischemia. The initial episode lasted for 60 s,
and every subsequent episode lasted for 30 s. The dur-
ation of cardioplegia delivery was selected on the basis
of previous work indicating that optimal myocardial pro-
tection with STH2 in the rat heart can be achieved when
the solution is infused for duration ≥ 30 s [11]. In the
hypothermia series, the cardioplegia dosage per episode
was lower than that in the normothermia series. Along
with an extended duration of global ischemia, the car-
dioplegia dosage was intentionally lowered to obtain a
greater amount of myocardial necrosis in the hypo-
thermic controls, from which we could derive stronger
conclusions about the extent of the protective effect of
each of the various cardioplegic solutions tested.The cardioplegic solutions
The chemical composition of the tested cardioplegic solu-
tions is presented in Table 1. The chemical composition of
the KHB was modified according to the following to create
the cardioplegic solution: [K+] was raised from 5.9 to 25
mmol/L; [Mg2+] was raised from 1.2 to 16 mmol/L; and














Dihydro orthophosphate 1.2 –
рН 7.8 7.8
Osmolarity, mOsm/l 380 310
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dioplegic solutions were not gassed with oxygen.Experimental protocol and exclusion criteria
In the hypothermia (22°C) series, hearts were allocated
into 1 of the following 3 groups:
1. Controls (CON-22, n = 8): global ischemia at 22°C
(no cardioplegia) for 180 min followed by 120 min
of reperfusion at 37°C.
2. Cardioplegia with modified KHB solution (mKHB-
22, n = 7): cardiac arrest for 180 min followed by
120 min of reperfusion at 37°C.
3. Cardioplegia with STH2 (STH2-22, n = 8): cardiac
arrest for 180 min followed by 120 min of
reperfusion at 37°C.
In the normothermia (37°C) series, hearts were allo-
cated to 1 of the following 3 groups:
1. Controls (CON-37, n = 8): global ischemia
(no cardioplegia) for 60 min followed by 120 min of
reperfusion.
2. Cardioplegia with modified KHB solution (mKHB-37,
n = 5): cardiac arrest for 60 min followed by 120 min
of reperfusion.
3. Cardioplegia with STH2 (STH2-37, n = 6): cardiac
arrest for 60 min followed by 120 min of
reperfusion.
LVSP, LVEDP, HR, and CFR were measured 5 min be-
fore global ischemia and at the 5th, 30th, 60th, and
120th min of reperfusion. In addition, the left ventricular
(LV) pressures were measured at the 5th, 15th, 25th,
35th, 45th, and 55th min of global ischemia in the nor-
mothermia series and during each 20 min of global is-
chemia in the hypothermia series.Any heart with a HR < 220 beats/min and a CFR > 18
or < 8 mL/min by the end of stabilization was excluded
from the study. Hearts failing to show a LVDP > 100
mm Hg when the LVEDP was maintained at < 10 mm
Hg were also excluded.
Infarct size determination
At the end of reperfusion, the hearts were rapidly cut
into 4 equally spaced transverse slices. The slices were
immersed in 1% solution of 2,3,5-triphenyltetrazolium
chloride (TTC) for 15 min at 37°С. The stained slices
were photographed with a digital camera for further de-
termination of the TTC-negative (infarcted) area. After
computer planimetry (Photoshop CS), the infarct size
was expressed as a percentage of total ventricular area
minus the cavities, and the mean value of all the sections
in a heart was used for the statistical analysis.
Statistical analysis
The continuous functional data and infarct size in the
text are expressed as mean ± standard deviation (SD).
The sample size per group was determined using the fol-
lowing parameters: SD values calculated on the basis of
previous studies, desired confidence level (95%), and
acceptable difference in outcome between the groups
(Statistics Calculator). The statistical analysis was per-
formed using the SPSS 20.0 software package. The
Kruskal-Wallis test was used to determine differences in
infarct size, followed by pairwise intergroup compari-
sons performed using nonparametric Mann–Whitney
U test. Differences in continuous data were tested using
repeated-measures analysis of variance, followed by a
Tukey post hoc test. P ≤ 0.05 was considered significant.
Results
Exclusions and rates of persistent ventricular fibrillation/
asystole during reperfusion
Of 42 hearts perfused, 4 were excluded during stabilization
(1 in the CON-22 group, 2 in the STH2-22 group, and 1
in the CON-37 group). The frequencies of persistent ven-
tricular fibrillation or asystole during reperfusion in the
hypothermia series were 0/7, 0/7, and 0/6 in the CON-22,
mKHB-22, and STH2-22 groups, respectively. In the nor-
mothermia series, the frequencies were 3/7, 0/5, and 0/6
in the CON-37, mKHB-37, and STH2-37 groups, respect-
ively. The hearts with persistent ventricular fibrillation/
asystole during reperfusion were not included in the ana-
lysis of postischemic LV function but were used for the de-
termination of infarct size.
Ischemic contracture
The dynamics of LV pressure during global ischemia
and cardioplegia in the hypothermia and normother-
mia series are shown in Figure 1A and B, respectively.
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increase in LV pressure at any time point of the ische-
mic period relative to the LV pressure after 5 min of
z`ischemia. No ischemic contracture was found in the
mKHB-22 group. The LV pressures during ische-
mia were significantly higher in the other hypother-
mic groups than in the mKHB-22 group (P < 0.001,
Figure 1A). In the normothermia series, the strongest
ischemic contracture was found in the CON-37 and
STH2-37 groups (Figure 1B). Ischemic contracture was
significantly lower in the mKHB-37 group than in the
other normothermic groups (e.g., P = 0.0004, vs. the
STH2-37 group).Figure 1 Hemodynamic parameters in the isolated rat hearts subjecte
normothermic condition (22°C or 37°C, respectively) followed by 120
hypothermia (A) and normothermia series (B); left ventricular developed pr
and left ventricular end-diastolic pressure (LVEDP) in the hypothermia (E) a
the controls subjected to 180-min ischemia and 120-min reperfusion (CON
cardioplegic solution (mKHB-22), and cardioplegia with St. Thomas’ Hospita
normothermia series: controls subjected to 60-min ischemia and 120-min r
buffer-based cardioplegic solution (mKHB-37), and cardioplegia with St. Tho
values. The data are the mean ± SD values. *P < 0.01; **P < 0.001; &P < 0.05Left ventricular developed pressure and end-diastolic
pressure
The baseline LVDPs and LVEDPs were similar between
all the groups. No spontaneous mechanical activity was
registered during ischemia, including the cardioplegia in-
fusion episodes, except at the beginning of the first
cardioplegia episode. In the control groups (at 22°C and
37°C), asystole started soon after the onset of global is-
chemia, though a bit later than after the start of
cardioplegia (2–3 min vs. 10–20 s). Representative LV
pressure recordings demonstrating different patterns of
postischemic LV function recovery are presented in
Figure 2. In the hypothermia groups, the LVDP recoveryd to global ischemia under either a hypothermic or
min of normothermic reperfusion. Ischemic contracture in the
essure (LVDP) in the hypothermia (C) and normothermia series (D);
nd normothermia series (F). Group legends in the hypothermia series:
-22), cardioplegia with the modified Krebs-Henseleit buffer-based
l cardioplegic solution No. 2 (STH2-22). Group legends in the
eperfusion (CON-37), cardioplegia with the modified Krebs-Henseleit
mas’ Hospital cardioplegic solution No. 2 (STH2-37). BL, baseline
; #P < 0.001; §P < 0.0001; ¶P < 0.0001; †P < 0.001.
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STH2-22 groups (Figure 1C). Among the normothermia
groups, the CON-37 group showed no cardiac contrac-
tion during the initial 5 min of reperfusion. The recovery
of LVDP in the STH2-37 group was not different from
that in the CON-37 group (Figure 1D). However, LVDP
recovery was significantly greater in the mKHB-37 group
than in the CON-37 and STH2-37 groups (P < 0.0001).
In the hypothermia series, the postischemic LVEDP was
significantly lower in the mKHB-22 and STH2-22 groups
than in the CON-22 group (P < 0.05, Figure 1E). In the
normothermia series, the postischemic LVEDP was signifi-
cantly lower in the STH2-37 group than in the CON-37
group (P < 0.0001, Figure 1F). The postischemic LVEDP
remained normal only in the mKHB-37 group (P < 0.001,
vs. the STH2-37 group; Figure 1F).Coronary flow rate and heart rate
The preischemic values of CFR and HR did not differ
between the groups (Tables 2 and 3). No important
intergroup and intragroup differences in CFR or HR
were found.Myocardial infarct size
The myocardial infarct size is depicted in Figure 3. Con-
trol ischemia with moderate hypothermia for 180 min
without cardioplegia (CON-22) resulted in an infarct sizeFigure 2 Representative LV pressure recordings demonstrating differ
STH2-22 (C), CON-37 (D), mKHB-37 (E), and STH2-37 (F) groups. See Fi
ventricular pressure.of 35 ± 7% after reperfusion for 120 min (Figure 3A,B). In
the hypothermia series, cardioplegia with mKHB and
STH2 reduced the infarct size in comparison with the
controls (5 ± 3% and 19 ± 9%, respectively; P = 0.0005 and
0.008, vs. the CON-22 group, respectively). In addition,
the infarct size was significantly smaller in the mKHB
group than in the STH2 group (P = 0.004). In the normo-
thermia series, the CON-37 and STH2-37 groups had no
difference in infarct size (72 ± 6% and 70 ± 12%, respect-
ively; Figure 3C,D). However, mKHB cardioplegia reduced
the infarct size (4 ± 3%; P = 0.0025, vs. the CON-37 and
STH2-37 groups, Figure 3C,D).
Discussion
The present study suggested that an mKHB-based car-
dioplegic solution had stronger infarct-limiting effect
and preserved postischemic ventricular function better
than STH2 after normothermic and moderately hypo-
thermic cardioplegia.
Myocardial temperature is a key factor in cardiac protec-
tion against ischemia [12,13]. Hypothermia slows down all
metabolic processes, contributing to prolonged tissue sur-
vival during ischemia [12,14]. However, deep hypothermia
itself may exert certain injurious effects [15]. During the
recent decades, the strategy of intraoperative myocardial
protection has changed from deep hypothermic toward
normothermic blood cardioplegia. In particular, a number
of clinical trials demonstrated excellent results with the useent patterns of LV function recovery in CON-22 (A), mKHB-22 (B),
gure 1 for the group legends. GI, global ischemia; LVP, left
Table 2 The values of coronary flow rate (ml/min) in the
experimental groups
Groups Baseline Reperfusion, min
5 30 60 120
CON-22 (n=7) 11.9±2.3 3.8±1.5 5.4±1.6 6.5±1.9 5.8±2.6
mKHB-22 (n=7) 10.2±2.6 4.5±2.3 6.7±1.6 6.1±1.8 4.2±1.7
STH2-22 (n=6) 13.2±3.5 5.3±2.5 6.7±2.2 7.5±4.6 5.5±2.1
CON-37 (n=7) 12.4±3.2 4.1±1.3 4.3±1.9 4.1±1.7 3.8±1.2
mKHB-37 (n=5) 10.4±1.9 6.6±4.0 6.2±1.7 6.3±0.6 5.2±1.4
STH2-37 (n=6) 11.2±1.8 5.6±3.9 4.6±2.1 3.3±0.7 3.1±0.9
Data are mean ± SD. Group legends in hypothermia series: controls subjected
to 180-min ischemia and 120-min reperfusion (CON-22), cardioplegia with
modified Krebs-Henseleit buffer-based cardioplegic solution (mKHB-22),
cardioplegia with St Thomas’ Hospital cardioplegic solution №2 (STH2-22).
Group legends in normothermia series: controls subjected to 60-min ischemia
and 120-min reperfusion (CON-37), cardioplegia with modified Krebs-Henseleit
buffer-based cardioplegic solution (mKHB-37), cardioplegia with St Thomas’
Hospital cardioplegic solution №2 (STH2-37).
Minasian et al. Journal of Cardiothoracic Surgery 2013, 8:60 Page 6 of 9
http://www.cardiothoracicsurgery.org/content/8/1/60of normothermic blood cardioplegia versus cold crystalloid
cardioplegia [4-6]. In normothermic cardioplegia protocols,
the temperature of the blood-based cardioplegic solution is
maintained at approximately 33°C to 37°C [16]. However,
many centers continue to use either cold crystalloid or cold
blood cardioplegia in their routine practice [17,18].
Documented experience with warm crystalloid cardio-
plegia is lacking. Hence, we conducted the present study
with the hope of contributing additional information
about the efficacy of mKHB-based cardioplegia by eluci-
dating its effects during normothermia and moderate
hypothermia. With temperatures of 5–10°C, the isolated
perfused rat hearts required cardioplegia arrest for >6 h
to obtain a significant ischemic injury. Therefore, we
chose the temperature of 22°С. This is beyond the
clinical relevance for cardioplegia, but it might be an
interesting future study for organ preservation forTable 3 The values of heart rate (beats/min) in the
experimental groups
Groups Baseline Reperfusion, min
5 30 60 120
CON-22 (n=7) 243±16 215±21 218±22 238±28 222±35
mKHB-22 (n=7) 253±25 218±32 219±29 246±34 251±28
STH2-22 (n=6) 256±14 227±28 216±22 245±35 236±32
CON-37 (n=7) 250±23 - 187±39 212±52 242±68
mKHB-37 (n=5) 268±21 191±39 195±24 211±32 232±58
STH2-37 (n=6) 269±13 180±35 187±37 223±47 224±12
Data are mean ± SD. Group legends in hypothermia series: controls subjected
to 180-min ischemia and 120-min reperfusion (CON-22), cardioplegia with
modified Krebs-Henseleit buffer-based cardioplegic solution (mKHB-22),
cardioplegia with St Thomas’ Hospital cardioplegic solution №2 (STH2-22).
Group legends in normothermia series: controls subjected to 60-min ischemia
and 120-min reperfusion (CON-37), cardioplegia with modified Krebs-Henseleit
buffer-based cardioplegic solution (mKHB-37), cardioplegia with St Thomas’
Hospital cardioplegic solution №2 (STH2-37).
“-” - persistent ventricular fibrillation/asystole in all hearts.transplantation. At both temperatures, mKHB-based car-
dio- plegia showed significantly improved
cardioprotection compared to that with STH2-based
cardioplegia. This finding may be attributed to a number
of factors.
Factor 1. A positive effect might be ascribed to the pres-
ence of glucose at a concentration of 11 mmol/L. Previous
experiments on isolated working rat hearts subjected to
hypothermic multidose cardioplegic arrest have demon-
strated that the supplementation of STH2 with 11 mmol/
L glucose resulted in better postischemic recovery in com-
parison with lower (1 mmol/L) and higher (20 and 50
mmol/L) glucose concentrations in STH2 [19]. Glucose at
a concentration of 11 mmol/L has been demonstrated to
stimulate glycolytic ATP production during ischemia,
whereas the use of higher glucose concentrations sup-
pressed this process. In addition, excessive glucose levels
may lead to cardiac myocyte injury because of osmotic
overload and increased risk of intracellular edema.
Factor 2. Although the optimal calcium concentration
is yet to be determined, we used 0.3 mmol/L in the
mKHB-based cardioplegic solution in this study. The
calcium content in the currently available cardioplegic
solutions varies from zero to physiological and even in-
creased levels. In a model of normothermic continuous
coronary perfusion of the isolated rat heart, Nakamura
et al. [10] demonstrated that the optimal calcium con-
centration in mKHB-based solution is 1.5 mmol/L. It
should be noted, however, that the heart subjected to
continuous coronary perfusion is much more sensitive
to calcium-induced injury at reperfusion as compared
with the heart undergoing intermittent cardioplegia,
suggesting that a lower calcium concentration (e.g., 0.3
mmol/L) might contribute to the attenuation of myocar-
dial injury via the prevention of intracellular calcium
overload. This hypothesis has been further supported by
the finding that the decrease in calcium concentration in
STH2 to 0.3–0.9 mmol/L resulted in enhanced post-
ischemic recovery of aortic flow in the isolated working
rat heart [20]. In this study cardioplegic solutions were
infused each 30 minute during global ischemia at 20°C
for 300 minutes. The use of acalcemic STH2 has been
associated with severe myocardial injury owing to the
calcium paradox. Of note, cardiac reperfusion after STH2
cardioplegia and 25-min normothermic arrest with perfus-
ate containing 0.25–1.0 mmol/L of calcium was not as-
sociated with additional protection in comparison with
cardioplegia itself [21].
Factor 3. The mKHB-based cardioplegic solution con-
tains bicarbonate and phosphate buffers that have equal
total inorganic buffer capacity to that of human plasma.
Such buffers minimize rapid changes in extracellular and
intracellular pH values during the bouts of ischemia-
reperfusion.
Figure 3 Myocardial infarct size after the 120-min reperfusion of the Langendorff-perfused rat hearts that were subjected to 60 or 180
min of global ischemia, sectioned, and stained with triphenyltetrazolium chloride. Infarct size in the hypothermia (A) and normothermia
series (C). The data are presented as dot plots with median values. The triphenyltetrazolium chloride-stained heart slices selected from the
representative experiments in each group in the hypothermia (B) and normothermia series (D). See Figure 1 for the group legends.
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sent study had an osmolarity of 380 mosm/L, which is
22.6% higher than that in STH2. This mild increase in
osmolarity may prevent myocardial edema during early
reperfusion.
The dynamics of LV pressure during global ischemia is
commonly used as a sensitive indicator of ischemic myo-
cardial injury [22]. In the present study, the use of
mKHB in the hypothermic mode prevented completely
ischemic contracture. In addition, normothermic mKHB-
based cardioplegia yielded the lowest levels of LV pressure
during ischemia among all of the normothermic options
applied. Meanwhile, using mKHB-based cardioplegia in
normothermic conditions, we observed a significant in-
crease in LV pressure during the final 15 min of global is-
chemia, which signaled the onset of ischemic contracture.
This fact indicates that the cardioprotective potential of
the modified mKHB solution may fail by this time.
To the best of our knowledge, the KHB has not previ-
ously been considered as a basis for a cardioplegic solu-
tion, at least for intermittent antegrade cardioplegia.
Some of the studies were aimed at improving myocardial
protection with STH2 by means of different modifica-
tions. In addition to the aforementioned changes in glu-
cose and calcium levels, improved protection was
demonstrated after oxygenation of STH2 [23] as well
as after supplementation with high-energy phosphates
[24] or antioxidants [25]. A recent study with the
Langendorff-perfused rat heart demonstrated that the
addition of inward rectifier potassium channel agonist
zacopride to the STH2 resulted in significant reduction
of infarct size and amelioration of LV function after 45
min of normothermic arrest [26].
During the 2 recent decades, several crystalloid car-
dioplegic solutions with enhanced cardioprotective prop-
erties have been developed and experimentally tested.
The protective efficacy of these novel solutions was
compared to that of the gold standard of crystalloid
cardioplegia, that is, STH2. For example, the extracellu-
lar cardioplegic solution MBS containing 10 mmol/L
glucose, 10 mmol/L L-aspartic acid, and 5 mmol/L
lactobionic acid was shown to be superior to STH2 in
the isolated working rat heart subjected to prolonged
hypothermic arrest [27]. Another crystalloid cardioplegic
solution has been developed on the basis of the non-
phosphate-buffered perfusion solution AqixW RS-I [28].
This magnesium-based solution provided better func-
tional LV recovery than STH2 after either single or mul-
tiple administrations in the Langendorff-perfused rat
heart with global ischemia at normothermia. The opti-
mal magnesium concentration was found to be 25
mmol/L, whereas the potassium content was kept at 5
mmol/L. In our study, the use of 16 mmol/L magnesium
was well justified by the presence of 25 mmol/Lpotassium in mKHB. The beneficial effect of the AqixW
RS-I- based cardioplegic solution could be
explained by the presence of 10 mmol/L glucose and
some other substrates/cofactors such as glutamate, as-
partate, choline, and cocarboxylase. Thus, we speculate
that the protective ability of mKHB could be further en-
hanced by the addition of these essential components.
The present study has several methodological limitations.
First, the many modifications and differences in the com-
position of the mKHB-based cardioplegia made it different
from the STH2 solution. Hence, we could not specify
which aspect made the mKHB solution superior to STH2.
However, the mKHB solution showed superior cardio-
protective abilities, in function and infarct size reduction, in
normothermia and moderate hypothermia. Second, the
numbers of hearts, especially in the normothermia series,
were rather small. Nevertheless, we were able to clearly
demonstrate the effects of the various solutions. Third, the
cardioplegic solutions were delivered at a relatively high
pressure of 85 mm Hg, which might have potentially re-
sulted in endothelial damage. In the clinical setting,
cardioplegia is usually delivered to the aorta at pressures
varying from 60 to 80 mm Hg. Although the perfusate
pressure was slightly higher than the usual, it was equal in
both cardioplegic solutions tested. Future studies are re-
quired to address these important issues. Finally, the vol-
ume of cardioplegic solutions infused was not measured.
The evidence obtained from our results may be con-
sidered adequate to prove the superiority of the new
mKHB solution to STH2. However, one may argue that
the isolated rat heart model is far from the clinical situ-
ation, and it is necessary to test the new solution in
more relevant models and against blood cardioplegia. In
this regard, it is important to note that the present
model is the model from which the St. Thomas’ Hospital
cardioplegic solution was developed.
Conclusions
The present data suggested that the KHB-based car-
dioplegic solution might be superior to the standard
crystalloid solution during moderate hypothermia and
normothermia.
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